Does the media refer more to TRDA or CGEM?

In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 2 articles in the media. Entrada Therapeutics' average media sentiment score of 1.60 beat Cullinan Therapeutics' score of 0.27 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MGTX or TRDA?

In the previous week, MeiraGTx had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.60 beat MeiraGTx's score of 0.87 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CRVS or TRDA?

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Entrada Therapeutics' average media sentiment score of 1.60 beat Corvus Pharmaceuticals' score of 1.11 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, CVAC or TRDA?

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Entrada Therapeutics $25.42M 11.51 -$143.75M -$3.99 N/A

Entrada Therapeutics (TRDA) Competitors

$7.54 +0.30 (+4.14%)

Closing price 04:00 PM Eastern

Extended Trading

$7.54 0.00 (0.00%)

As of 05:44 PM Eastern

Compare

TRDA vs. COLL, CGEM, MGTX, CRVS, and CVAC

Should you buy Entrada Therapeutics stock or one of its competitors? MarketBeat compares Entrada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entrada Therapeutics include Collegium Pharmaceutical (COLL), Cullinan Therapeutics (CGEM), MeiraGTx (MGTX), Corvus Pharmaceuticals (CRVS), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

How does Entrada Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Collegium Pharmaceutical has a net margin of 9.41% compared to Entrada Therapeutics' net margin of -2,895.05%. Collegium Pharmaceutical's return on equity of 95.18% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

In the previous week, Entrada Therapeutics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 2 mentions for Entrada Therapeutics and 0 mentions for Collegium Pharmaceutical. Entrada Therapeutics' average media sentiment score of 1.60 beat Collegium Pharmaceutical's score of 1.50 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Collegium Pharmaceutical	Very Positive
Entrada Therapeutics	Very Positive

86.4% of Entrada Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Collegium Pharmaceutical has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

Collegium Pharmaceutical currently has a consensus price target of $57.50, suggesting a potential upside of 61.61%. Entrada Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 132.10%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Collegium Pharmaceutical has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.44
Entrada Therapeutics	$25.42M	11.51	-$143.75M	-$3.99	N/A

Summary

Collegium Pharmaceutical beats Entrada Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Cullinan Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Entrada Therapeutics and Entrada Therapeutics both had 2 articles in the media. Entrada Therapeutics' average media sentiment score of 1.60 beat Cullinan Therapeutics' score of 0.27 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cullinan Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Entrada Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 132.10%. Cullinan Therapeutics has a consensus price target of $32.00, indicating a potential upside of 81.30%. Given Entrada Therapeutics' higher possible upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Entrada Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Entrada Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.51	-$143.75M	-$3.99	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Summary

Entrada Therapeutics beats Cullinan Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Entrada Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MeiraGTx presently has a consensus target price of $25.83, suggesting a potential upside of 122.70%. Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 132.10%. Given Entrada Therapeutics' higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

MeiraGTx has a net margin of -151.12% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

In the previous week, MeiraGTx had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.60 beat MeiraGTx's score of 0.87 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MeiraGTx has higher revenue and earnings than Entrada Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	13.20	-$114.20M	-$1.48	N/A
Entrada Therapeutics	$25.42M	11.51	-$143.75M	-$3.99	N/A

MeiraGTx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Summary

MeiraGTx beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Corvus Pharmaceuticals currently has a consensus price target of $33.33, suggesting a potential upside of 157.16%. Entrada Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 132.10%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Corvus Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Entrada Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Entrada Therapeutics	$25.42M	11.51	-$143.75M	-$3.99	N/A

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Entrada Therapeutics' average media sentiment score of 1.60 beat Corvus Pharmaceuticals' score of 1.11 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Corvus Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Corvus Pharmaceuticals' return on equity of -38.92% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Summary

Corvus Pharmaceuticals beats Entrada Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Entrada Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

CureVac has a net margin of 199.92% compared to Entrada Therapeutics' net margin of -2,895.05%. CureVac's return on equity of -23.03% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

17.3% of CureVac shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Entrada Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Entrada Therapeutics and 0 mentions for CureVac. Entrada Therapeutics' average media sentiment score of 1.60 beat CureVac's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Entrada Therapeutics	Very Positive

CureVac currently has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 132.10%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Entrada Therapeutics	$25.42M	11.51	-$143.75M	-$3.99	N/A

Summary

CureVac beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$281.06M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	N/A	20.68	25.17	23.98
Price / Sales	11.51	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.94	8.26	10.76	6.41
Net Income	-$143.75M	$23.91M	$3.56B	$337.14M
7 Day Performance	10.72%	3.05%	1.37%	-0.48%
1 Month Performance	14.94%	2.40%	0.81%	0.49%
1 Year Performance	6.50%	56.35%	30.53%	28.16%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	4.0116 of 5 stars	$7.54 +4.1%	$17.50 +132.1%	+2.8%	$281.06M	$25.42M	N/A	110	Positive News
COLL Collegium Pharmaceutical	3.0231 of 5 stars	$34.62 +3.5%	$57.50 +66.1%	+15.9%	$1.08B	$780.57M	16.97	210	News Coverage Positive News
CGEM Cullinan Therapeutics	3.3055 of 5 stars	$17.75 +2.6%	$32.00 +80.3%	+134.2%	$1.06B	N/A	N/A	30
MGTX MeiraGTx	3.3396 of 5 stars	$11.81 +2.9%	$25.83 +118.7%	+87.2%	$1.06B	$81.39M	N/A	300
CRVS Corvus Pharmaceuticals	3.836 of 5 stars	$12.63 +0.6%	$33.33 +163.9%	+238.6%	$1.06B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. COLL, CGEM, MGTX, CRVS, and CVAC

How does Entrada Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Entrada Therapeutics compare to Cullinan Therapeutics?

Summary

How does Entrada Therapeutics compare to MeiraGTx?

Summary

How does Entrada Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Entrada Therapeutics compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. COLL, CGEM, MGTX, CRVS, and CVAC

How does Entrada Therapeutics compare to Collegium Pharmaceutical?

Is COLL or TRDA more profitable?

Does the media prefer COLL or TRDA?

Do institutionals and insiders have more ownership in COLL or TRDA?

Which has more risk and volatility, COLL or TRDA?

Do analysts rate COLL or TRDA?

Which has stronger earnings and valuation, COLL or TRDA?

Summary

How does Entrada Therapeutics compare to Cullinan Therapeutics?

Does the media refer more to TRDA or CGEM?

Is TRDA or CGEM more profitable?

Do analysts recommend TRDA or CGEM?

Which has more risk & volatility, TRDA or CGEM?

Do insiders & institutionals believe in TRDA or CGEM?

Which has better earnings & valuation, TRDA or CGEM?

Summary

How does Entrada Therapeutics compare to MeiraGTx?

Do insiders & institutionals hold more shares of MGTX or TRDA?

Do analysts prefer MGTX or TRDA?

Is MGTX or TRDA more profitable?

Does the media prefer MGTX or TRDA?

Which has stronger valuation and earnings, MGTX or TRDA?

Which has more volatility and risk, MGTX or TRDA?

Summary

How does Entrada Therapeutics compare to Corvus Pharmaceuticals?

Do analysts prefer CRVS or TRDA?

Which has more volatility & risk, CRVS or TRDA?

Which has stronger earnings and valuation, CRVS or TRDA?

Do insiders & institutionals hold more shares of CRVS or TRDA?

Does the media favor CRVS or TRDA?

Is CRVS or TRDA more profitable?

Summary

How does Entrada Therapeutics compare to CureVac?

Is CVAC or TRDA more profitable?

Which has more volatility & risk, CVAC or TRDA?

Do institutionals & insiders have more ownership in CVAC or TRDA?

Does the media prefer CVAC or TRDA?

Do analysts recommend CVAC or TRDA?

Which has higher valuation and earnings, CVAC or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools